Profiling MMV portfolio compound activity against the complete P. berghei liver stage.Scope includes compound screenings and portfolio compound testing where data will be delivered within 2 weeks of the end of the test run.

The major goal of this project is to use a new tool like CRISPR/Cas13d to cleave HIV RNA. An HIV RNA-targeting strategy that efficiently and simultaneously targets multiple conserved sites , will result in the eradication of HIV from the cells.

Many genes including those associated with viral infections undergo differential splicing in different human populations. The aim of this study is to identify and quantify these differences and investigate their role in differential antiviral immunity among human populations.

In 2017, an estimated 10 million people developed TB disease, demonstrating an urgent need for new approaches to therapy, including host-directed therapy (HDT), to halt infection and progression of active TB. To this end, the overall goal of our ongoing research program is to identify intracellular ?master regulators? of inflammation and metabolic intermediates that dictate human macrophage responses to Mycobacterium tuberculosis infection as a strategy to identify potential host cell targets for HDT.

The objective of this research proposal is to further prove the concept that peptide mimics of the protective epitopes of PI-LPS are sufficient to confer protective immunity against C. burnetii aerosol infection. As a subcontract, Dr. Zhang will provide expert advice and guidance in experimental designing, data interpretation and problems solving as needed by ZenVax LLC in support of this project. In order to facilitate the ZenVax LLC’s effort to develop a mimotope vaccine against Q fever, Dr.

Coxiella burnetii is an obligate intracellular Gram-negative bacterium that causes acute and chronic Q fever in humans. There is an urgent need to create a safe and effective vaccine for prevention of human Q fever. However, the mechanisms of vaccine-induced immunity against C. burnetii natural infection remain unclear. The long-term goal of this project is to develop a safe and effective vaccine against Q fever.

Presidents of San Antonio’s four largest research institutions today announced they are providing $800,000, collectively, for a major initiative in precision therapeutics. The process of precision therapeutics ultimately leads to breakthrough treatments that can be individualized to specific patient populations.

Southwest Research Institute has received new funding from the Medical Technology Enterprise Consortium (MTEC) and the Food and Drug Administration (FDA) to use an SwRI-developed bioreactor to propagate cells for personalized regenerative medicine applications. A $3 million MTEC program will demonstrate stem cell manufacturing, and a $2.3 FDA contract is funding CAR T-cell production.